Anticholinergic Medication Selection

Introduction to Glycopyrrolate

• The American Academy of Child and Adolescent Psychiatry guidelines state that glycopyrrolate is an acceptable anticholinergic for use in ECT procedures, alongside atropine, specifically because of its favorable side effect profile 1, 2
• Multiple guidelines specifically recommend glycopyrrolate over other anticholinergics when CNS effects must be minimized 1, 2, 3

Comparison with Other Anticholinergics

• The Anesthesiology guidelines note that scopolamine may prolong sedation and disorientation in patients under general anesthesia 3
• Scopolamine crosses the blood-brain barrier and is more likely to cause delirium compared to glycopyrrolate 4, 5
• While effective peripherally, atropine should be avoided when CNS effects are a concern 3

Clinical Applications

• Glycopyrrolate is effective for reducing salivation and respiratory secretions with dosing of 0.2-0.4 mg IV or subcutaneously every 4 hours 4, 5
• Standard dosing for preanesthetic medication is 0.004 mg/kg intramuscularly given 30-60 minutes before anesthesia 1, 4

Important Considerations

• Domperidone carries significant cardiovascular risks including QT prolongation and ventricular tachycardia 6
• Domperidone is only available in the United States through FDA investigational drug application, limiting its practical use 6